Melanoma is a type of skin cancer that begins in skin cells called melanocytes. Although it accounts for only about 1% of skin cancers, it causes a large majority of skin cancer deaths. Anti-PD-1 monoclonal antibodies like Merck's Keytruda and Bristol Myers Squibb's Opdivo are mostly used to treat melanoma and have significantly improved survival outcomes in patients with advanced melanoma. However, a subset of patients develop resistance to PD-1 inhibition.
The company we are profiling today is Replimune Group Inc. (REPL), a clinical-stage biotechnology company that has developed a treatment for anti-PD1 failed melanoma.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.